We started in vivo treatment of MLL-ALL xenografts with dexamethasone (30 mg/kg intraperitoneally once daily) when hCD45+ ALL cell chimerism reached 20% or higher in the recipient PB, then followed PB human ALL chimerism by flow cytometry every week thereafter. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.